Oligonucleotide Synthesis Market - Global Forecast To 2030
商品番号 : SMB-24262
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年6月 |
| ページ数 | 456 |
| 図表数 | 645 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
この調査レポートでは、オリゴヌクレオチド合成市場を、製品（オリゴヌクレオチドベースの医薬品、合成オリゴヌクレオチド、試薬と消耗品、機器）、用途（治療用途、研究用途、診断用途）、エンドユーザー（病院、製薬およびバイオテクノロジー企業、診断研究所、CROおよびCMO、学術研究機関）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。
本レポートは、オリゴヌクレオチド合成市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーを徹底的に分析し、事業概要、ソリューション、サービス、主要戦略、新製品・新サービスの発売、買収、オリゴヌクレオチド合成市場に関連する最近の動向に関する洞察を提供しています。本レポートは、オリゴヌクレオチド合成市場エコシステムにおける新興企業の競合分析も網羅しています。
The oligonucleotide synthesis market is projected to reach USD 24.7 billion by 2030 from USD 10.5 billion in 2025, at a CAGR of 18.6% during the forecast period. The growth of this market is driven by several factors, such as the increasing demand for synthesized oligonucleotides like primers & probes for several research & diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.
オリゴヌクレオチド合成市場は、2025年の105億米ドルから2030年には247億米ドルに達すると予測されており、予測期間中は年平均成長率（CAGR）18.6%で成長すると見込まれています。この市場の成長は、様々な研究・診断用途におけるプライマーやプローブなどの合成オリゴヌクレオチドの需要増加など、複数の要因によって牽引されています。また、オリゴヌクレオチド合成における技術の進歩も、予測期間中の市場成長に寄与すると予想されます。
By product, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2024.
By products, the market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment accounted for the largest share of the market. The large share of this segment can be attributed to the growing acceptance of these treatments and their proven success, especially for rare & hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2024, by application, the therapeutic applications segment accounted for the largest share of the market.
The oligonucleotide synthesis market is segmented into therapeutic applications, research applications, and diagnostic applications. In 2024, the therapeutic applications segment accounted for the largest share of the market. The growth of this market is fueled by the use of oligos such as antisense and siRNA for the treatment of neurological & rare diseases, with ongoing research aiming to expand applications into the treatment of CVD and cancer. Advancements in synthesis technology are expected to fuel the demand for efficient & cost-effective therapeutic approaches, with a comprehensive understanding of molecular disease mechanisms ensuring the discovery of innovative therapeutic targets, thereby contributing to market growth in this segment.
In 2024, North America accounted for the largest share of the oligonucleotide synthesis market.
In 2024, North America accounted for the largest market share, a dominance fueled by the strong presence of key industry players and a significant surge in research initiatives dedicated to advancing oligonucleotide-based therapeutics. Additionally, North America’s well-established healthcare infrastructure and favorable reimbursement policies facilitate the widespread adoption of these innovative treatments, consequently driving research applications in the region. The concentration of numerous global entities also significantly contributes to this market leadership.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives – 30%, Directors- 45%, and Others- 25%
- By Region: North America -35%, Europe – 25%, the Asia Pacific -15%, Latin America -10%, the Middle East- 10%, and Africa- 5%
Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering products for research & diagnostic applications.
Biogen (US). Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies profiled in the report offering products for therapeutic applications.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by Product (Oligonucleotide-based drugs, synthesized oligonucleotide, reagents & consumables, and equipment), application (therapeutic applications, research applications, and diagnostic applications), end user (hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, CROs & CMOs, and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).
The report’s scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oligonucleotide synthesis market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following :
- Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing pharma R&D investments in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
- Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the oligonucleotide synthesis market across varied regions.
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market.
- Pipeline Analysis: Comprehensive information about products under clinical trials.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others offering products for research & diagnostic applications. Other companies include Biogen (US), Alnylam Pharmaceuticals, Inc. (US), and Sarepta Therapeutics, Inc. (US), among others, for the therapeutic applications segment.
Table of Contents
1 INTRODUCTION 43
1.1 STUDY OBJECTIVES 43
1.2 MARKET DEFINITION 43
1.3 INCLUSIONS & EXCLUSIONS 44
1.4 MARKET SCOPE 45
1.4.1 YEARS CONSIDERED 46
1.4.2 CURRENCY CONSIDERED 46
1.5 RESEARCH LIMITATIONS 46
1.6 STAKEHOLDERS 47
1.7 SUMMARY OF CHANGES 47
2 RESEARCH METHODOLOGY 48
2.1 RESEARCH DATA 48
2.1.1 SECONDARY DATA 49
2.1.2 PRIMARY DATA 50
2.2 MARKET SIZE ESTIMATION 51
2.2.1 MARKET SIZE ASSESSMENT, SEGMENT LEVEL 55
2.3 MARKET GROWTH FORECAST 56
2.4 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME ESTIMATION 58
2.5 MARKET BREAKDOWN & DATA TRIANGULATION 59
2.6 STUDY ASSUMPTIONS 60
2.7 RISK ANALYSIS 60
3 EXECUTIVE SUMMARY 61
4 PREMIUM INSIGHTS 64
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 64
4.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET,
BY APPLICATION & COUNTRY (2024) 65
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2025 VS. 2030 65
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2024 66
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 66
5 MARKET OVERVIEW 67
5.1 INTRODUCTION 67
5.2 MARKET DYNAMICS 67
5.2.1 DRIVERS 68
5.2.1.1 Increasing use of synthesized oligos in therapeutic &
diagnostic applications 68
5.2.1.2 Technological advancements 70
5.2.1.3 Growing government investments in life science research &
synthetic biology 71
5.2.1.4 Growing focus on precision/personalized medicine 72
5.2.2 RESTRAINTS 72
5.2.2.1 Complexities associated with therapeutic oligonucleotides 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Increasing R&D investments by key players in emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Lack of standard regulations 74
5.2.4.2 Delivery of oligonucleotide drugs to specific targets 74
5.3 INDUSTRY TRENDS 74
5.3.1 GROWING FOCUS ON DEVELOPMENT OF DRUG DELIVERY TECHNOLOGIES FOR OLIGONUCLEOTIDE-BASED DRUGS 74
5.3.2 GROWING FOCUS ON TECHNOLOGY DEVELOPMENT FOR SUSTAINABLE & LARGE-SCALE SYNTHESIS OF OLIGONUCLEOTIDES 75
5.3.3 FOCUS ON ACQUISITIONS TO ENHANCE MARKET POSITION 76
5.3.4 GROWING USE OF ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS FOR TREATMENT OF NEUROLOGICAL & RARE DISEASES 77
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 78
5.5 VALUE CHAIN ANALYSIS 79
5.6 ECOSYSTEM ANALYSIS 82
5.6.1 ROLE IN ECOSYSTEM 83
5.7 TECHNOLOGY ANALYSIS 83
5.7.1 KEY TECHNOLOGIES 84
5.7.1.1 Solid-phase synthesis 84
5.7.1.2 Liquid-phase synthesis 84
5.7.1.3 Enzymatic oligo synthesis 85
5.7.2 COMPLEMENTARY TECHNOLOGIES 85
5.7.2.1 Polymerase chain reaction (PCR) 85
5.7.2.2 Next-generation sequencing 85
5.7.2.3 Microarray analysis 86
5.7.3 ADJACENT TECHNOLOGIES 86
5.7.3.1 CRISPR 86
5.7.3.2 Lipid nanoparticles 86
5.8 PRICING ANALYSIS 87
5.8.1 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024 87
5.8.2 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, 2022−2024 89
5.8.3 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE-BASED DRUGS,
BY KEY PLAYERS, 2022−2024 89
5.8.4 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,
BY REGION, 2024 91
5.8.5 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,
BY KEY PLAYERS, 2024 93
5.8.6 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE-BASED DRUGS,
BY REGION, 2024 94
5.9 PATENT ANALYSIS 94
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 94
5.10 PIPELINE ANALYSIS 97
5.11 TRADE ANALYSIS 99
5.11.1 IMPORT DATA (HS CODE 293499) 99
5.11.2 EXPORT DATA (HS CODE 293499) 101
5.12 KEY CONFERENCES & EVENTS, 2025–2026 102
5.13 TARIFF & REGULATORY LANDSCAPE 104
5.13.1 TARIFF DATA (HS CODE 2934.99, 3822.00) 104
5.13.1.1 Trade policy updates affecting oligonucleotide synthesis market, 2022−2025 104
5.13.1.2 Impact of Tariffs on pricing & supply chain 105
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 105
5.13.3 REGULATORY FRAMEWORK 108
5.14 PORTER’S FIVE FORCES ANALYSIS 108
5.14.1 DEGREE OF COMPETITION 109
5.14.2 BARGAINING POWER OF SUPPLIERS 109
5.14.3 BARGAINING POWER OF BUYERS 109
5.14.4 THREAT OF SUBSTITUTES 109
5.14.5 THREAT OF NEW ENTRANTS 109
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 110
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
5.15.2 BUYING CRITERIA FOR END USERS 111
5.16 CASE STUDY ANALYSIS 113
5.16.1 CASE STUDY 1: THERMO FISHER SCIENTIFIC LEVERAGED ITS OLIGONUCLEOTIDE SYNTHESIS EXPERTISE TO DELIVER LARGE-SCALE
DYE-LABELED OLIGONUCLEOTIDES TO ITS CLIENT 113
5.16.2 CASE STUDY 2: BAKER LAB UTILIZING TWIST BIOSCIENCES OLIGO POOLS FOR EVALUATING PROTEIN FOLDING 113
5.16.3 CASE STUDY 3: ENHANCED MOTOR FUNCTION WITH SPINRAZA TREATMENT IN ADOLESCENTS WITH LATE-ONSET SMA 114
5.17 INVESTMENT/FUNDING SCENARIO 114
5.18 IMPACT OF GENERATIVE AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET 116
5.19 TRUMP TARIFF IMPACT OVERVIEW: OLIGONUCLEOTIDE SYNTHESIS MARKET 118
5.19.1 KEY TARIFF RATES 119
5.19.2 PRICE IMPACT ANALYSIS 120
5.19.3 KEY IMPACT ON VARIOUS REGIONS 121
5.19.3.1 US 121
5.19.3.2 Europe 121
5.19.3.3 APAC 122
5.19.3.4 Rest of the World 122
5.19.4 END-USE INDUSTRY IMPACT 122
5.19.4.1 Hospitals 122
5.19.4.2 Pharmaceutical & biotechnology companies 123
5.19.4.3 Diagnostic laboratories 123
5.19.4.4 CROs & CDMOs 123
5.19.4.5 Academic & research institutes 123
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 124
6.1 INTRODUCTION 125
6.2 OLIGONUCLEOTIDE-BASED DRUGS 125
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE 129
6.2.1.1 Antisense oligonucleotide-based drugs 130
6.2.1.1.1 Growing use of antisense oligos in oligonucleotide-based drugs to boost growth 130
6.2.1.2 siRNA oligonucleotide-based drugs 135
6.2.1.2.1 Large pipeline of products to favor market growth 135
6.2.1.3 Other oligonucleotide-based drugs 139
6.3 SYNTHESIZED OLIGONUCLEOTIDES 142
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 145
6.3.1.1 Primers 145
6.3.1.1.1 Increasing applications of oligo primers in DNA sequencing and molecular diagnostics to drive growth 145
6.3.1.2 Probes 149
6.3.1.2.1 Advancements in molecular diagnostic technologies such as FISH and qPCR to support market growth 149
6.3.1.3 DNA oligonucleotides 152
6.3.1.3.1 Diverse usage of DNA oligos to support market growth 152
6.3.1.4 RNA oligonucleotides 155
6.3.1.4.1 Growing diagnostic and therapeutic applications of RNA oligos to propel growth 155
6.3.1.5 Other synthesized oligonucleotides 158
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 161
6.3.2.1 Custom oligonucleotides 161
6.3.2.1.1 Increasing demand for custom oligonucleotides for therapeutic research studies to drive growth 161
6.3.2.2 Predesigned oligonucleotides 165
6.3.2.2.1 Ability of predesigned oligos to save time required in design and optimization to boost adoption 165
6.4 REAGENTS & CONSUMABLES 168
6.4.1 GROWING DEMAND FOR OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO DRIVE MARKET GROWTH FOR REAGENTS 168
6.5 EQUIPMENT 171
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO DRIVE GROWTH IN EQUIPMENT MARKET 171
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 174
7.1 INTRODUCTION 175
7.2 THERAPEUTIC APPLICATIONS 175
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE 179
7.2.1.1 Neurological disorders 179
7.2.1.1.1 Growing research on oligonucleotide-based drugs for treatment of DMD and SMA to drive market 179
7.2.1.2 Rare diseases 183
7.2.1.2.1 High specificity & efficacy of oligo-based drugs against rare diseases to support growth 183
7.2.1.3 Other diseases 186
7.3 RESEARCH APPLICATIONS 189
7.3.1 PCR 192
7.3.1.1 Increasing use of PCR in molecular biology research to drive market 192
7.3.2 SEQUENCING 195
7.3.2.1 Advancements in sequencing technologies & low cost of DNA sequencing to boost market 195
7.3.3 OTHER RESEARCH APPLICATIONS 198
7.4 DIAGNOSTIC APPLICATIONS 201
7.4.1 INCREASING DEMAND FOR RAPID & SPECIFIC METHODS FOR DISEASE DETECTION SUPPORT MARKET GROWTH 201
8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 205
8.1 INTRODUCTION 206
8.2 HOSPITALS 206
8.2.1 INCREASING FDA APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS FOR RARE DISEASES TO DRIVE MARKET 206
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 210
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY & THERAPEUTICS TO PROPEL MARKET 210
8.4 DIAGNOSTIC LABORATORIES 213
8.4.1 RISING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO
FUEL MARKET 213
8.5 CONTRACT RESEARCH ORGANIZATIONS (CROS) & CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 216
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO SUPPORT
MARKET GROWTH 216
8.6 ACADEMIC RESEARCH INSTITUTES 220
8.6.1 GROWING USE OF OLIGOS FOR GENOMIC RESEARCH APPLICATIONS TO PROPEL MARKET 220
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 224
9.1 INTRODUCTION 225
9.2 NORTH AMERICA 226
9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 227
9.2.2 US 231
9.2.2.1 Government initiatives and strategic developments by leading players to drive market 231
9.2.3 CANADA 235
9.2.3.1 Strong research infrastructure and availability of funding to support market growth 235
9.3 EUROPE 239
9.3.1 EUROPE: MACROECONOMIC OUTLOOK 239
9.3.2 GERMANY 244
9.3.2.1 Government & private funding investments towards health research to drive market 244
9.3.3 UK 248
9.3.3.1 Strategic collaborations & partnerships between key market players to fuel market 248
9.3.4 FRANCE 251
9.3.4.1 Favorable government initiatives for genomics research to
boost demand 251
9.3.5 ITALY 255
9.3.5.1 Increasing R&D expenditure for pharma & biotech companies to support market growth 255
9.3.6 SPAIN 258
9.3.6.1 Favorable funding investments for biomedical research to
drive market 258
9.3.7 REST OF EUROPE 261
9.4 ASIA PACIFIC 265
9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 265
9.4.2 CHINA 269
9.4.2.1 Expansion of leading pharmaceutical & biotechnology companies to drive market 269
9.4.3 JAPAN 273
9.4.3.1 Growing research initiatives & strategic developments to
boost demand 273
9.4.4 INDIA 276
9.4.4.1 Development of bioclusters and improvements in healthcare infrastructure to propel market 276
9.4.5 AUSTRALIA 279
9.4.5.1 Increasing government initiatives and research funding to support market growth 279
9.4.6 SOUTH KOREA 283
9.4.6.1 Growing research activities and strategic expansions in oligonucleotide synthesis to aid market 283
9.4.7 REST OF ASIA PACIFIC 286
9.5 LATIN AMERICA 290
9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 290
9.5.2 BRAZIL 294
9.5.2.1 Availability of leading oligo-based therapies to support
market growth 294
9.5.3 MEXICO 297
9.5.3.1 Growing adoption of NGS technology to drive market 297
9.5.4 ARGENTINA 300
9.5.4.1 Increasing research collaborations and government support to
boost market 300
9.5.5 REST OF LATIN AMERICA 304
9.6 MIDDLE EAST 307
9.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 307
9.6.2 GCC COUNTRIES 311
9.6.2.1 Saudi Arabia (KSA) 314
9.6.2.1.1 Increasing focus on research & government support to propel market 314
9.6.2.2 United Arab Emirates (UAE) 318
9.6.2.2.1 Growing focus on life sciences research to fuel market 318
9.6.2.3 Other GCC countries 321
9.6.3 REST OF MIDDLE EAST 324
9.7 AFRICA 327
9.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT
MARKET GROWTH 327
9.7.2 AFRICA: MACROECONOMIC OUTLOOK 327
10 COMPETITIVE LANDSCAPE 331
10.1 INTRODUCTION 331
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 331
10.3 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS) 336
10.3.1 REVENUE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022−2024 336
10.3.2 REVENUE ANALYSIS (THERAPEUTIC APPLICATIONS), 2022−2024 337
10.4 MARKET SHARE ANALYSIS 337
10.4.1 MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 338
10.4.2 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS),2024 339
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 340
10.5.1 STARS 340
10.5.2 EMERGING LEADERS 340
10.5.3 PERVASIVE PLAYERS 340
10.5.4 PARTICIPANTS 340
10.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024 341
10.6.1 STARS 342
10.6.2 EMERGING LEADERS 342
10.6.3 PERVASIVE PLAYERS 342
10.6.4 PARTICIPANTS 342
10.6.5 COMPANY FOOTPRINT: 344
10.6.5.1 Company footprint (Research & diagnostic applications) 344
10.6.5.2 Region footprint (Research & diagnostic applications) 345
10.6.5.3 Product footprint (Research & diagnostic applications) 346
10.6.5.4 Application footprint (Research & diagnostic applications) 346
10.6.5.5 Company footprint (Therapeutic applications) 347
10.6.5.6 Region footprint (Therapeutic applications) 347
10.6.5.7 Product footprint (Therapeutic applications) 348
10.6.5.8 Application footprint (Therapeutic applications) 348
10.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 349
10.7.1 PROGRESSIVE COMPANIES 349
10.7.2 RESPONSIVE COMPANIES 349
10.7.3 DYNAMIC COMPANIES 349
10.7.4 STARTING BLOCKS 349
10.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 351
10.7.5.1 Detailed list of key startups/SMEs 351
10.7.5.2 Competitive benchmarking of startups/SMEs 352
10.8 COMPANY VALUATION & FINANCIAL METRICS 353
10.8.1 FINANCIAL METRICS (RESEARCH & DIAGNOSTIC APPLICATIONS) 353
10.8.2 COMPANY VALUATION (RESEARCH & DIAGNOSTIC APPLICATIONS) 353
10.8.3 FINANCIAL METRICS (THERAPEUTIC APPLICATIONS) 354
10.8.4 COMPANY VALUATION (THERAPEUTIC APPLICATIONS) 354
10.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 355
10.9.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT
(RESEARCH & DIAGNOSTIC APPLICATIONS) 355
10.9.2 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT
(THERAPEUTIC APPLICATIONS) 356
10.10 COMPETITIVE SCENARIO 357
10.10.1 PRODUCT APPROVALS 357
11 COMPANY PROFILES 360
11.1 KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS) 360
11.1.1 DANAHER CORPORATION 360
11.1.1.1 Business overview 360
11.1.1.2 Products offered 361
11.1.1.3 Recent developments 365
11.1.1.3.1 Deals 365
11.1.1.3.2 Expansions 365
11.1.1.3.3 Other developments 366
11.1.1.4 MnM view 366
11.1.1.4.1 Key strengths 366
11.1.1.4.2 Strategic choices 366
11.1.1.4.3 Weaknesses & competitive threats 366
11.1.2 THERMO FISHER SCIENTIFIC INC. 367
11.1.2.1 Business overview 367
11.1.2.2 Products offered 368
11.1.2.3 Recent developments 371
11.1.2.3.1 Deals 371
11.1.2.4 MnM view 371
11.1.2.4.1 Key strengths 371
11.1.2.4.2 Strategic choices 371
11.1.2.4.3 Weaknesses & competitive threats 371
11.1.3 MERCK KGAA 372
11.1.3.1 Business overview 372
11.1.3.2 Products offered 373
11.1.3.3 Recent developments 376
11.1.3.3.1 Deals 376
11.1.3.3.2 Expansions 376
11.1.3.4 MnM view 377
11.1.3.4.1 Key strengths 377
11.1.3.4.2 Strategic choices 377
11.1.3.4.3 Weaknesses & competitive threats 377
11.1.4 LGC LIMITED 378
11.1.4.1 Business overview 378
11.1.4.2 Products offered 379
11.1.4.3 Recent developments 381
11.1.4.3.1 Deals 381
11.1.4.3.2 Expansions 382
11.1.4.4 MnM view 382
11.1.4.4.1 Key strengths 382
11.1.4.4.2 Strategic choices 382
11.1.4.4.3 Weaknesses & competitive threats 382
11.1.5 EUROFINS SCIENTIFIC 383
11.1.5.1 Business overview 383
11.1.5.2 Products offered 384
11.1.5.3 Recent developments 385
11.1.5.3.1 Deals 385
11.1.5.3.2 Expansions 386
11.1.5.4 MnM view 386
11.1.5.4.1 Key strengths 386
11.1.5.4.2 Strategic choices 386
11.1.5.4.3 Weaknesses & competitive threats 386
11.1.6 AGILENT TECHNOLOGIES, INC. 387
11.1.6.1 Business overview 387
11.1.6.2 Products offered 388
11.1.6.3 Recent developments 389
11.1.6.3.1 Deals 389
11.1.6.3.2 Expansions 390
11.1.7 KANEKA CORPORATION 391
11.1.7.1 Business overview 391
11.1.7.2 Products offered 392
11.1.7.3 Recent developments 394
11.1.7.3.1 Expansions 394
11.1.8 MARAVAI LIFESCIENCES 395
11.1.8.1 Business overview 395
11.1.8.2 Products offered 396
11.1.8.3 Recent developments 399
11.1.8.3.1 Deals 399
11.1.8.3.2 Expansions 399
11.1.9 AZENTA US INC. 400
11.1.9.1 Business overview 400
11.1.9.2 Products offered 401
11.1.10 TWIST BIOSCIENCE 403
11.1.10.1 Business overview 403
11.1.10.2 Products offered 404
11.1.10.3 Recent developments 405
11.1.10.3.1 Deals 405
11.1.11 GENSCRIPT 406
11.1.11.1 Business overview 406
11.1.11.2 Products offered 407
11.1.11.3 Recent developments 409
11.1.11.3.1 Deals 409
11.1.11.3.2 Expansions 409
11.2 KEY PLAYERS (THERAPEUTIC APPLICATIONS) 410
11.2.1 BIOGEN 410
11.2.1.1 Business overview 410
11.2.1.2 Products offered 411
11.2.1.3 Recent developments 412
11.2.1.3.1 Product approvals 412
11.2.1.3.2 Deals 412
11.2.1.3.3 Expansions 413
11.2.1.4 MnM view 413
11.2.1.4.1 Key strengths 413
11.2.1.4.2 Strategic choices 413
11.2.1.4.3 Weaknesses & competitive threats 413
11.2.2 ALNYLAM PHARMACEUTICALS, INC. 414
11.2.2.1 Business overview 414
11.2.2.2 Products offered 415
11.2.2.3 Recent developments 416
11.2.2.3.1 Product approvals 416
11.2.2.3.2 Deals 417
11.2.2.4 MnM view 417
11.2.2.4.1 Key strengths 417
11.2.2.4.2 Strategic choices 417
11.2.2.4.3 Weaknesses & competitive threats 417
11.2.3 SAREPTA THERAPEUTICS, INC. 418
11.2.3.1 Business overview 418
11.2.3.2 Products offered 419
11.2.3.3 Recent developments 420
11.2.3.3.1 Product approvals 420
11.2.3.3.2 Expansions 420
11.2.3.4 MnM view 420
11.2.3.4.1 Key strengths 420
11.2.3.4.2 Strategic choices 420
11.2.3.4.3 Weaknesses & competitive threats 420
11.2.4 ASTRAZENECA 421
11.2.4.1 Business overview 421
11.2.4.2 Products offered 422
11.2.4.3 Recent developments 423
11.2.4.3.1 Deals 423
11.2.4.3.2 Product Approvals 423
11.2.4.4 MnM view 423
11.2.4.4.1 Key strengths 423
11.2.4.4.2 Strategic choices 423
11.2.4.4.3 Weaknesses & competitive threats 423
11.2.5 ASTELLAS PHARMA INC. 424
11.2.5.1 Business overview 424
11.2.5.2 Products offered 425
11.2.5.3 Recent developments 426
11.2.5.3.1 Deals 426
11.2.5.3.2 Product approvals 426
11.2.5.4 MnM view 426
11.2.5.4.1 Key strengths 426
11.2.5.4.2 Strategic choices 426
11.2.5.4.3 Weaknesses & competitive threats 426
11.2.6 JAZZ PHARMACEUTICALS PLC 427
11.2.6.1 Business overview 427
11.2.6.2 Products offered 428
11.2.7 NIPPON SHINYAKU, CO. LTD. 429
11.2.7.1 Business overview 429
11.2.7.2 Products offered 430
11.2.7.3 Recent developments 431
11.2.7.3.1 Deals 431
11.2.8 IONIS PHARMACEUTICALS, INC. 432
11.2.8.1 Business overview 432
11.2.8.2 Products offered 433
11.2.8.3 Recent developments 434
11.2.8.3.1 Product Approvals 434
11.2.8.3.2 Deals 434
11.2.9 NOVARTIS AG 436
11.2.9.1 Business overview 436
11.2.9.2 Products offered 437
11.2.9.3 Recent developments 438
11.2.9.3.1 Product Approvals 438
11.2.9.3.2 Deals 438
11.3 OTHER PLAYERS 439
11.3.1 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S) 439
11.3.2 BIOLEGIO B.V. 440
11.3.3 BIOLYTIC LAB PERFORMANCE, INC. 441
11.3.4 BIOCOMMA LIMITED 442
11.3.5 REVVITY (SUBSIDIARY OF HORIZON DISCOVERY LTD.) 443
11.3.6 BIO-SYNTHESIS, INC. 444
11.3.7 CREATIVE BIOGENE 445
11.3.8 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE) 447
12 APPENDIX 448
12.1 DISCUSSION GUIDE 448
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 452
12.3 CUSTOMIZATION OPTIONS 454
12.4 RELATED REPORTS 454
12.5 AUTHOR DETAILS 455
LIST OF TABLES
TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS 68
TABLE 2 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES (2016−2025) 69
TABLE 3 LIST OF ACQUISITIONS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 76
TABLE 4 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 78
TABLE 5 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS, BY KEY PLAYERS, 2022−2024 87
TABLE 6 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS,
BY KEY PLAYERS, 2022-2024 89
TABLE 7 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,
BY REGION, 2024 91
TABLE 8 AVERAGE SELLING PRICE FOR OLIGONUCLEOTIDE-BASED DRUGS,
BY REGION, 2024 94
TABLE 9 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 96
TABLE 10 IMPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 99
TABLE 11 IMPORT VOLUME FOR HS CODE 293499-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (TONS) 100
TABLE 12 EXPORT VALUE OF HS CODE 293499-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (USD THOUSAND) 101
TABLE 13 EXPORT VOLUME FOR HS CODE 9027-COMPLIANT PRODUCTS FOR
TOP 20 COUNTRIES, 2020–2024 (TONS)S 102
TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES & EVENTS 102
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 105
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 106
TABLE 18 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 107
TABLE 19 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 107
TABLE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: PORTER’S FIVE FORCES ANALYSIS 108
TABLE 21 KEY COMPANIES IMPLEMENTING AI 117
TABLE 22 US ADJUSTED RECIPROCAL TARIFF RATES 119
TABLE 23 KEY PRODUCT-RELATED TARIFF: MISCELLANEOUS CHEMICAL PRODUCTS, PHARMACEUTICAL PRODUCTS, ORGANIC CHEMICALS. 120
TABLE 24 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 121
TABLE 25 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 125
TABLE 26 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 27 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 28 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 29 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 30 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 31 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 32 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET VOLUME, BY PRODUCT,
2023–2030 (NUMBER OF VIALS) 129
TABLE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 130
TABLE 35 APPROVED ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS 131
TABLE 36 ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2023–2030 (USD MILLION) 132
TABLE 37 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 38 EUROPE: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 39 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 40 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 41 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 42 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 43 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS 135
TABLE 44 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2023–2030 (USD MILLION) 136
TABLE 45 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 46 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 137
TABLE 47 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 48 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 49 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 50 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 51 APPROVED OTHER OLIGONUCLEOTIDE-BASED DRUGS 139
TABLE 52 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION,
2023–2030 (USD MILLION) 140
TABLE 53 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 54 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 140
TABLE 55 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 56 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 57 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 58 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 59 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION,
2023–2030 (USD MILLION) 143
TABLE 60 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 61 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 143
TABLE 62 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 63 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 64 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 144
TABLE 65 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 66 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 145
TABLE 67 OLIGONUCLEOTIDE PRIMERS MARKET, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 68 NORTH AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 146
TABLE 69 EUROPE: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 70 ASIA PACIFIC: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 72 MIDDLE EAST: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 73 GCC COUNTRIES: OLIGONUCLEOTIDE PRIMERS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 148
TABLE 74 OLIGONUCLEOTIDE PROBES MARKET, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 75 NORTH AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 76 EUROPE: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 77 ASIA PACIFIC: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 78 LATIN AMERICA: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 79 MIDDLE EAST: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 80 GCC COUNTRIES: OLIGONUCLEOTIDE PROBES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 81 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 153
TABLE 82 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 83 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 84 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 154
TABLE 85 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 154
TABLE 86 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 154
TABLE 87 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 155
TABLE 88 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 156
TABLE 89 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 90 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 156
TABLE 91 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 92 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 93 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 157
TABLE 94 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 158
TABLE 95 OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION,
2023–2030 (USD MILLION) 159
TABLE 96 NORTH AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 97 EUROPE: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 98 ASIA PACIFIC: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 99 LATIN AMERICA: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 100 MIDDLE EAST: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 101 GCC COUNTRIES: OTHER SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 102 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 161
TABLE 103 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 104 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 105 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 106 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 107 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 108 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 109 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 164
TABLE 110 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION,
2023–2030 (USD MILLION) 165
TABLE 111 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 112 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 166
TABLE 113 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 166
TABLE 114 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 115 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 167
TABLE 116 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 117 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET,
BY REGION, 2023–2030 (USD MILLION) 168
TABLE 118 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 119 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 120 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 121 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 122 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 123 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 124 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION,
2023–2030 (USD MILLION) 171
TABLE 125 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 126 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 127 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 172
TABLE 128 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 129 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 130 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 131 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 175
TABLE 132 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 176
TABLE 133 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 134 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 135 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 136 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 137 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 138 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 139 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE TYPE, 2023–2030 (USD MILLION) 179
TABLE 140 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS,
BY REGION, 2023–2030 (USD MILLION) 180
TABLE 141 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 142 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 143 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 144 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 145 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2023–2030 (USD MILLION) 182
TABLE 146 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY REGION,
2023–2030 (USD MILLION) 183
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 152 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES,
BY REGION, 2023–2030 (USD MILLION) 185
TABLE 153 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RARE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 154 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY REGION, 2023–2030 (USD MILLION) 186
TABLE 155 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 156 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 157 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2030 (USD MILLION) 187
TABLE 158 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 159 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES,
BY REGION, 2023–2030 (USD MILLION) 188
TABLE 160 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 161 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 189
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 167 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 191
TABLE 168 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 191
TABLE 169 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION,
2023–2030 (USD MILLION) 192
TABLE 170 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 171 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY,
2023–2030 (USD MILLION) 193
TABLE 172 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 173 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 174 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY REGION, 2023–2030 (USD MILLION) 194
TABLE 175 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PCR, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 176 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING, BY REGION,
2023–2030 (USD MILLION) 196
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,
BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 178 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,
BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 179 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,
BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 180 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,
BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 181 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,
BY REGION, 2023–2030 (USD MILLION) 197
TABLE 182 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SEQUENCING,
BY COUNTRY, 2023–2030 (USD MILLION) 198
TABLE 183 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 199
TABLE 184 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 185 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 186 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 187 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 188 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 200
TABLE 189 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 190 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 202
TABLE 191 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 192 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 193 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 194 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 195 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 203
TABLE 196 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 197 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 206
TABLE 198 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION,
2023–2030 (USD MILLION) 207
TABLE 199 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 200 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 201 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 202 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 203 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,
BY REGION, 2023–2030 (USD MILLION) 209
TABLE 204 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 205 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 211
TABLE 206 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 207 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 208 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 209 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 212
TABLE 210 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 212
TABLE 211 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 213
TABLE 212 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES,
BY REGION, 2023–2030 (USD MILLION) 214
TABLE 213 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 214 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 214
TABLE 215 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 216 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 217 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 215
TABLE 218 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION) 216
TABLE 219 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION,
2023–2030 (USD MILLION) 217
TABLE 220 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 221 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 222 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 223 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 224 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,
BY REGION, 2023–2030 (USD MILLION) 219
TABLE 225 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 226 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 221
TABLE 227 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 221
TABLE 228 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 221
TABLE 229 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 230 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 231 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 232 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 223
TABLE 233 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2023–2030 (USD MILLION) 225
TABLE 234 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 227
TABLE 235 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 228
TABLE 236 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 228
TABLE 237 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 229
TABLE 238 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 229
TABLE 239 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 229
TABLE 240 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 230
TABLE 241 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 230
TABLE 242 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 231
TABLE 243 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 232
TABLE 244 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 245 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 233
TABLE 246 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 233
TABLE 247 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 234
TABLE 248 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE TYPE, 2023–2030 (USD MILLION) 234
TABLE 249 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 250 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 235
TABLE 251 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 236
TABLE 252 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 236
TABLE 253 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 237
TABLE 254 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 237
TABLE 255 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 237
TABLE 256 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 238
TABLE 257 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 238
TABLE 258 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 238
TABLE 259 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 241
TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 241
TABLE 261 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 242
TABLE 262 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 242
TABLE 263 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 242
TABLE 264 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 243
TABLE 265 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 243
TABLE 266 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 243
TABLE 267 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 244
TABLE 268 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 245
TABLE 269 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 245
TABLE 270 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 246
TABLE 271 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 246
TABLE 272 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 246
TABLE 273 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 247
TABLE 274 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 247
TABLE 275 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 276 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 249
TABLE 277 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 249
TABLE 278 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 249
TABLE 279 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 250
TABLE 280 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 250
TABLE 281 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS,
BY DISEASE TYPE, 2023–2030 (USD MILLION) 250
TABLE 282 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 251
TABLE 283 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 251
TABLE 284 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 252
TABLE 285 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 252
TABLE 286 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 253
TABLE 287 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 253
TABLE 288 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 253
TABLE 289 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 254
TABLE 290 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 254
TABLE 291 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 254
TABLE 292 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 255
TABLE 293 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 294 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 256
TABLE 295 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 256
TABLE 296 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 257
TABLE 297 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 257
TABLE 298 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 257
TABLE 299 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 258
TABLE 300 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 259
TABLE 301 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 259
TABLE 302 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 259
TABLE 303 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 260
TABLE 304 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 260
TABLE 305 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 260
TABLE 306 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 261
TABLE 307 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 261
TABLE 308 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 262
TABLE 309 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 262
TABLE 310 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 263
TABLE 311 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 263
TABLE 312 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 263
TABLE 313 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 264
TABLE 314 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 264
TABLE 315 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 264
TABLE 316 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 266
TABLE 317 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 266
TABLE 318 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 267
TABLE 319 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 267
TABLE 320 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 267
TABLE 321 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 268
TABLE 322 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 268
TABLE 323 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 324 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 269
TABLE 325 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 270
TABLE 326 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 270
TABLE 327 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 271
TABLE 328 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 271
TABLE 329 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 271
TABLE 330 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 272
TABLE 331 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 272
TABLE 332 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 272
TABLE 333 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 273
TABLE 334 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 274
TABLE 335 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 274
TABLE 336 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 274
TABLE 337 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 275
TABLE 338 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 275
TABLE 339 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 340 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 276
TABLE 341 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 277
TABLE 342 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 277
TABLE 343 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 277
TABLE 344 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 278
TABLE 345 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 278
TABLE 346 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 278
TABLE 347 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2023–2030 (USD MILLION) 279
TABLE 348 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 279
TABLE 349 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 280
TABLE 350 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 280
TABLE 351 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 281
TABLE 352 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 281
TABLE 353 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 281
TABLE 354 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 282
TABLE 355 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 356 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 282
TABLE 357 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 283
TABLE 358 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 359 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 284
TABLE 360 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 284
TABLE 361 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 285
TABLE 362 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 285
TABLE 363 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 364 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 286
TABLE 365 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 287
TABLE 366 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 287
TABLE 367 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 288
TABLE 368 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 288
TABLE 369 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 288
TABLE 370 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 289
TABLE 371 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 372 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 289
TABLE 373 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 290
TABLE 374 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 291
TABLE 375 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 291
TABLE 376 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 292
TABLE 377 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 292
TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 292
TABLE 379 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 293
TABLE 380 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 381 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 293
TABLE 382 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 294
TABLE 383 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 294
TABLE 384 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 295
TABLE 385 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 295
TABLE 386 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 295
TABLE 387 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 296
TABLE 388 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 389 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 296
TABLE 390 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 297
TABLE 391 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 298
TABLE 392 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 298
TABLE 393 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 298
TABLE 394 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 299
TABLE 395 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 299
TABLE 396 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 299
TABLE 397 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 300
TABLE 398 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 301
TABLE 399 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 301
TABLE 400 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 302
TABLE 401 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 302
TABLE 402 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 302
TABLE 403 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 303
TABLE 404 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 303
TABLE 405 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 303
TABLE 406 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 304
TABLE 407 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 304
TABLE 408 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 305
TABLE 409 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 305
TABLE 410 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 305
TABLE 411 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 306
TABLE 412 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 306
TABLE 413 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 306
TABLE 414 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION,
2023–2030 (USD MILLION) 307
TABLE 415 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 308
TABLE 416 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 308
TABLE 417 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 309
TABLE 418 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 309
TABLE 419 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 309
TABLE 420 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 310
TABLE 421 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 310
TABLE 422 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 310
TABLE 423 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 311
TABLE 424 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 311
TABLE 425 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 312
TABLE 426 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 312
TABLE 427 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 312
TABLE 428 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 313
TABLE 429 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 313
TABLE 430 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 313
TABLE 431 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 314
TABLE 432 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 315
TABLE 433 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 315
TABLE 434 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 316
TABLE 435 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 316
TABLE 436 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 316
TABLE 437 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 317
TABLE 438 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 317
TABLE 439 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 317
TABLE 440 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 318
TABLE 441 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 319
TABLE 442 UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 319
TABLE 443 UNITED ARAB EMIRATES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 319
TABLE 444 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 320
TABLE 445 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 320
TABLE 446 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 320
TABLE 447 UNITED ARAB EMIRATES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 321
TABLE 448 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 321
TABLE 449 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 322
TABLE 450 OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 322
TABLE 451 OTHER GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 322
TABLE 452 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 323
TABLE 453 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 323
TABLE 454 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 323
TABLE 455 OTHER GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 324
TABLE 456 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 324
TABLE 457 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2023–2030 (USD MILLION) 325
TABLE 458 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 325
TABLE 459 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2023–2030 (USD MILLION) 325
TABLE 460 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 326
TABLE 461 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 326
TABLE 462 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 326
TABLE 463 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2023–2030 (USD MILLION) 327
TABLE 464 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 328
TABLE 465 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE,
2023–2030 (USD MILLION) 328
TABLE 466 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 329
TABLE 467 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE,
2023–2030 (USD MILLION) 329
TABLE 468 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 329
TABLE 469 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2023–2030 (USD MILLION) 330
TABLE 470 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION) 330
TABLE 471 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2023–2030 (USD MILLION) 330
TABLE 472 STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2025 332
TABLE 473 STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS), 2022–2025 334
TABLE 474 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): DEGREE OF COMPETITION 338
TABLE 475 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):
DEGREE OF COMPETITION 339
TABLE 476 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): REGIONAL FOOTPRINT 345
TABLE 477 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): PRODUCT FOOTPRINT 346
TABLE 478 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): APPLICATION FOOTPRINT 346
TABLE 479 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):
REGION FOOTPRINT 347
TABLE 480 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):
PRODUCT FOOTPRINT 348
TABLE 481 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS): APPLICATION FOOTPRINT 348
TABLE 482 DETAILED LIST OF KEY STARTUPS/SMES 351
TABLE 483 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 352
TABLE 484 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS,
JANUARY 2022–MAY 2025 357
TABLE 485 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2022-MAY 2025 358
TABLE 486 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025 359
TABLE 487 DANAHER CORPORATION: COMPANY OVERVIEW 360
TABLE 488 DANAHER CORPORATION: PRODUCTS OFFERED 361
TABLE 489 DANAHER CORPORATION: DEALS, JANUARY 2021−MAY 2025 365
TABLE 490 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025 365
TABLE 491 DANAHER CORPORATION: OTHER DEVELOPMENTS 366
TABLE 492 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 367
TABLE 493 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 368
TABLE 494 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021−MAY 2025 371
TABLE 495 MERCK KGAA: COMPANY OVERVIEW 372
TABLE 496 MERCK KGAA: PRODUCTS OFFERED 373
TABLE 497 MERCK KGAA: DEALS, JANUARY 2021−MAY 2025 376
TABLE 498 MERCK KGAA: EXPANSIONS, JANUARY 2021−MAY 2025 376
TABLE 499 LGC LIMITED: COMPANY OVERVIEW 378
TABLE 500 LGC LIMITED: PRODUCTS OFFERED 379
TABLE 501 LGC LIMITED: DEALS, JANUARY 2021−MAY 2025 381
TABLE 502 LGC LIMITED: EXPANSIONS, JANUARY 2021−MAY 2025 382
TABLE 503 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 383
TABLE 504 EUROFINS SCIENTIFIC: PRODUCTS OFFERED 384
TABLE 505 EUROFINS SCIENTIFIC: DEALS, JANUARY 2021−MAY 2025 385
TABLE 506 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2021−MAY 2025 386
TABLE 507 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 387
TABLE 508 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 388
TABLE 509 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021−MAY 2025 389
TABLE 510 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021−MAY 2025 390
TABLE 511 KANEKA CORPORATION: COMPANY OVERVIEW 391
TABLE 512 KANEKA CORPORATION: PRODUCTS OFFERED 392
TABLE 513 KANEKA CORPORATION: EXPANSIONS, JANUARY 2021−MAY 2025 394
TABLE 514 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 395
TABLE 515 MARAVAI LIFESCIENCES: PRODUCTS OFFERED 396
TABLE 516 MARAVAI LIFESCIENCES: DEALS, JANUARY 2021−MAY 2025 399
TABLE 517 MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2021−MAY 2025 399
TABLE 518 AZENTA US INC.: COMPANY OVERVIEW 400
TABLE 519 AZENTA US INC.: PRODUCTS OFFERED 401
TABLE 520 TWIST BIOSCIENCE: COMPANY OVERVIEW 403
TABLE 521 TWIST BIOSCIENCE: PRODUCTS OFFERED 404
TABLE 522 TWIST BIOSCIENCE: DEALS, JANUARY 2021−MAY 2025 405
TABLE 523 GENSCRIPT: COMPANY OVERVIEW 406
TABLE 524 GENSCRIPT: PRODUCTS OFFERED 407
TABLE 525 GENSCRIPT: DEALS, JANUARY 2021−MAY 2025 409
TABLE 526 GENSCRIPT: EXPANSIONS, JANUARY 2021−MAY 2025 409
TABLE 527 BIOGEN: COMPANY OVERVIEW 410
TABLE 528 BIOGEN: PRODUCTS OFFERED 411
TABLE 529 BIOGEN: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 412
TABLE 530 BIOGEN: DEALS, JANUARY 2021−MAY 2025 412
TABLE 531 BIOGEN: EXPANSIONS, JANUARY 2021−MAY 2025 413
TABLE 532 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 414
TABLE 533 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED 415
TABLE 534 ALNYLAM PHARMACEUTICALS INC.: PRODUCT APPROVALS,
JANUARY 2021−MAY 2025 416
TABLE 535 ALNYLAM PHARMACEUTICALS INC.: DEALS, JANUARY 2021−MAY 2025 417
TABLE 536 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW 418
TABLE 537 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED 419
TABLE 538 SAREPTA THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 420
TABLE 539 SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2021−MAY 2025 420
TABLE 540 ASTRAZENECA: COMPANY OVERVIEW 421
TABLE 541 ASTRAZENECA: PRODUCTS OFFERED 422
TABLE 542 ASTRAZENECA: DEALS, JANUARY 2021−MAY 2025 423
TABLE 543 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 423
TABLE 544 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 424
TABLE 545 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 425
TABLE 546 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021−MAY 2025 426
TABLE 547 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 426
TABLE 548 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW 427
TABLE 549 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED 428
TABLE 550 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW 429
TABLE 551 NIPPON SHINYAKU, CO. LTD.: PRODUCTS OFFERED 430
TABLE 552 NIPPON SHINYAKU, CO. LTD.: DEALS, JANUARY 2021−MAY 2025 431
TABLE 553 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 432
TABLE 554 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED 433
TABLE 555 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 434
TABLE 556 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−MAY 2025 434
TABLE 557 NOVARTIS AG: COMPANY OVERVIEW 436
TABLE 558 NOVARTIS AG: PRODUCTS OFFERED 437
TABLE 559 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021−MAY 2025 438
TABLE 560 NOVARTIS AG: DEALS, JANUARY 2021−MAY 2025 438
TABLE 561 OLIGOMAKER APS: COMPANY OVERVIEW 439
TABLE 562 BIOLEGIO B.V.: COMPANY OVERVIEW 440
TABLE 563 BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW 441
TABLE 564 BIOCOMMA LIMITED: COMPANY OVERVIEW 442
TABLE 565 REVVITY: COMPANY OVERVIEW 443
TABLE 566 BIO-SYNTHESIS, INC.: COMPANY OVERVIEW 444
TABLE 567 CREATIVE BIOGENE: COMPANY OVERVIEW 445
TABLE 568 REPROCELL INC.: COMPANY OVERVIEW 447
LIST OF FIGURES
FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION 45
FIGURE 2 RESEARCH DESIGN 48
FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 50
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2024 51
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1A (REVENUE SHARE ANALYSIS FOR RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 52
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1B (REVENUE SHARE ANALYSIS FOR THERAPEUTIC APPLICATIONS), 2024 52
FIGURE 7 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION (RESEARCH & DIAGNOSTIC APPLICATIONS): REVENUE SHARE ANALYSIS, 2024 53
FIGURE 8 ILLUSTRATIVE EXAMPLE OF BIOGEN INC. (THERAPEUTIC APPLICATIONS):
REVENUE SHARE ANALYSIS, 2024 53
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 55
FIGURE 10 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 55
FIGURE 11 CAGR PROJECTIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET, 2025–2030 57
FIGURE 12 CAGR PROJECTIONS: OLIGONUCLEOTIDE-BASED DRUGS MARKET
(THERAPEUTIC APPLICATIONS), 2025–2030 57
FIGURE 13 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES IN OLIGONUCLEOTIDE SYNTHESIS MARKET 58
FIGURE 14 DATA TRIANGULATION METHODOLOGY 59
FIGURE 15 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT,
2025 VS. 2030 (USD MILLION) 61
FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION,
2025 VS. 2030 (USD MILLION) 62
FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER,
2024−2029 (USD MILLION) 62
FIGURE 18 GEOGRAPHIC SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET 63
FIGURE 19 RISING DEMAND FOR SYNTHESIZED OLIGOS FOR DRUG DISCOVERY & DEVELOPMENT TO DRIVE MARKET 64
FIGURE 20 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR MARKET
SHARE IN US IN 2O24 65
FIGURE 21 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2030 65
FIGURE 22 THERAPEUTIC APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 66
FIGURE 23 NORTH AMERICA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 66
FIGURE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 67
FIGURE 25 REVENUE SHIFT AND NEW REVENUE POCKETS FOR
OLIGONUCLEOTIDE MANUFACTURERS 78
FIGURE 26 VALUE CHAIN ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 80
FIGURE 27 VALUE CHAIN ANALYSIS (THERAPEUTIC APPLICATIONS)—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 81
FIGURE 28 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET 82
FIGURE 29 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE
SYNTHESIS PRODUCTS, 2022−2024 89
FIGURE 30 AVERAGE PRICING TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS,
BY KEY PLAYERS, 2024 93
FIGURE 31 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2014–DECEMBER 2024) 95
FIGURE 32 OLIGONUCLEOTIDE DRUGS PIPELINE, BY DISEASE 97
FIGURE 33 OLIGONUCLEOTIDE DRUGS PIPELINE, BY PHASE 98
FIGURE 34 OLIGONUCLEOTIDE DRUGS PIPELINE, BY REGION 98
FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 110
FIGURE 36 STAKEHOLDERS INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS: HOSPITALS 110
FIGURE 37 BUYING CRITERIA OF END USERS FOR SYNTHESIZED
OLIGONUCLEOTIDE PRODUCTS 111
FIGURE 38 BUYING CRITERIA OF HOSPITALS FOR SYNTHESIZED
OLIGONUCLEOTIDE PRODUCTS 112
FIGURE 39 NIH FUNDING FOR OLIGONUCLEOTIDE SYNTHESIS PROJECTS, 2014–2024 115
FIGURE 40 AI USE CASES 117
FIGURE 41 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 226
FIGURE 42 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT 240
FIGURE 43 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS
(RESEARCH & DIAGNOSTIC APPLICATIONS), 2022–2024 336
FIGURE 44 OLIGONUCLEOTIDE SYNTHESIS MARKET: REVENUE ANALYSIS
(THERAPEUTIC APPLICATIONS), 2022–2024 337
FIGURE 45 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE ANALYSIS (RESEARCH & DIAGNOSTIC APPLICATIONS), BY KEY PLAYER, 2024 338
FIGURE 46 MARKET SHARE ANALYSIS (THERAPEUTIC APPLICATIONS), BY KEY PLAYER, 2024 339
FIGURE 47 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (RESEARCH & DIAGNOSTIC APPLICATIONS), 2024 341
FIGURE 48 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX FOR
KEY PLAYERS (THERAPEUTIC APPLICATIONS), 2024 343
FIGURE 49 OLIGONUCLEOTIDE SYNTHESIS MARKET (RESEARCH & DIAGNOSTIC APPLICATIONS): COMPANY FOOTPRINT 344
FIGURE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET (THERAPEUTIC APPLICATIONS):
COMPANY FOOTPRINT 347
FIGURE 51 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX
FOR STARTUPS/SMES, 2024 350
FIGURE 52 EV/EBITDA OF KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS) 353
FIGURE 53 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS (RESEARCH & DIAGNOSTIC APPLICATIONS) 353
FIGURE 54 EV/EBITDA OF KEY VENDORS (THERAPEUTIC APPLICATIONS) 354
FIGURE 55 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS (THERAPEUTIC APPLICATIONS) 354
FIGURE 56 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT
(RESEARCH & DIAGNOSTIC APPLICATIONS) 355
FIGURE 57 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT
(THERAPEUTIC APPLICATIONS) 356
FIGURE 58 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 361
FIGURE 59 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 368
FIGURE 60 MERCK KGAA: COMPANY SNAPSHOT (2024) 373
FIGURE 61 LGC LIMITED: COMPANY SNAPSHOT (2024) 379
FIGURE 62 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024) 384
FIGURE 63 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 388
FIGURE 64 KANEKA CORPORATION: COMPANY SNAPSHOT (2024) 392
FIGURE 65 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2024) 396
FIGURE 66 AZENTA US INC.: COMPANY SNAPSHOT (2024) 401
FIGURE 67 TWIST BIOSCIENCE: COMPANY SNAPSHOT (2024) 404
FIGURE 68 GENSCRIPT: COMPANY SNAPSHOT (2024) 407
FIGURE 69 BIOGEN: COMPANY SNAPSHOT (2024) 411
FIGURE 70 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 415
FIGURE 71 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2024) 419
FIGURE 72 ASTRAZENECA: COMPANY SNAPSHOT (2024) 422
FIGURE 73 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024) 425
FIGURE 74 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2024) 428
FIGURE 75 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2024) 430
FIGURE 76 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024) 432
FIGURE 77 NOVARTIS AG: COMPANY SNAPSHOT (2024) 437
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- サプライチェーンマネジメント（SCM）市場 – 2030年までの世界予測 2025-07-08
- バイオセンサー市場 – 2030年までの世界予測 2025-07-08
- In situ ハイブリダイゼーション（ISH）市場 – 2030年までの世界予測 2025-07-08
- 燃料電池市場 – 2030年までの世界予測 2025-07-08
- 施設管理市場 – 2030年までの世界予測 2025-07-07